Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
about
Targeting ischemic penumbra Part I: from pathophysiology to therapeutic strategyThe exact science of stroke thrombolysis and the quiet art of patient selectionDiagnosis and management of acute ischemic stroke: speed is criticalIntracerebral haemorrhage: an often neglected medical emergencyKnowledge of risk factors and warning signs of strokeOptimizing the Economic Impact of rtPA Use in a Stroke Belt State: The Case of South CarolinaCreating a Novel Video Vignette Stroke Preparedness Outcome Measure Using a Community-Based Participatory Approach.Development and Validation of a Bilingual Stroke Preparedness Assessment Instrument.Stroke Ready Intervention: Community Engagement to Decrease Prehospital Delay.Mobile Telestroke During Ambulance Transport Is Feasible in a Rural EMS Setting: The iTREAT Study.Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokeNinety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke.Endovascular thrombectomy following acute ischemic stroke: a single-center case series and critical review of the literature.Etiologic subtype predicts outcome in mild stroke: prospective data from a hospital stroke registry.Thrombolytic therapy at systemic lupus onset with secondary antiphospholipid syndrome. A rare stroke experience.Association between the perfusion/diffusion and diffusion/FLAIR mismatch: data from the AXIS2 trialAcute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke.Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.Neuroimaging of ischemic stroke with CT and MRI: advancing towards physiology-based diagnosis and therapy.Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence.Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection.Acute ischemic stroke therapy.Stroke neuroprotection: targeting mitochondriaEndovascular Management of Stroke Patients with Large Vessel Occlusion and Minor Stroke SymptomsRecombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.Wake-up stroke and stroke of unknown onset: a critical review.Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms.Patient awareness and perception of stroke symptoms and the use of 911Blood pressure management in stroke: Five new things.Trends in thrombolytic use for ischemic stroke in the United States.Merci Retriever in acute stroke treatment.Efficiency of enrollment in a successful phase II acute stroke clinical trial.Intravenous tissue plasminogen activator for patients with minor ischemic stroke.The Comparison of Outcome between Thromboaspiration and Aggressive Mechanical Clot Disruption in Treating Hyperacute Stroke PatientsRetention of motor changes in chronic stroke survivors who were administered mental practice.Clinical translation of nitrite therapy for cardiovascular diseases.Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms.
P2860
Q24622248-F1E198A8-BFBC-48A6-B348-2D49E4A96532Q27011873-31C24E9D-508F-401F-9010-A64B46DDC193Q28085439-1FE309E6-A029-402C-AF63-181488DCE8DBQ28212587-466F059F-5611-48A6-95F4-BC028FC8102AQ28219244-1AF25FA7-D167-4419-9B41-C3A65FE6AE0CQ28386540-BBF86646-B711-4F4C-9ACA-32A9A712259CQ30151195-E33187B8-4336-495B-8520-14CD76B33BE7Q30151229-8442CF64-6FD0-42D9-8137-89A7C4719BE4Q30152021-F1F1DC69-4192-41DB-A504-41ED5997DF02Q30278030-A6C987CA-DFBB-4E2F-A5F1-C387F3788491Q30414441-6F2BCB80-6F32-4F4F-8FA5-E8B0304D21A2Q30422705-A1B197EA-5F7C-4888-842C-59EBAE73F228Q30436396-B1272AEB-A34F-406E-B279-055C326C3A77Q30683526-7024C65F-4B7F-4E7C-9940-8E093ED85295Q30886508-85783AB0-4A2A-419F-B488-D968EA054D53Q30964058-F2BC0C96-10FA-49EB-922A-6F2C14B906C0Q33286104-8BA90A90-FCAC-475F-BA24-0E4F787B85A9Q33335930-9C1CED3E-A3F8-42FF-A063-91D343E2CFAAQ33395470-94865E5C-57D8-44E8-97C1-A7A446916279Q33525255-26AA8B8E-98A6-41C4-86AB-B5EBE0271E35Q33594546-4C3DE032-7732-4954-8848-2CED1FFE3694Q33714948-866EBA4F-1093-4601-A769-41AFD608B357Q33772138-E3DE1A56-7736-4CA0-A774-E12E73462D22Q33905200-1E90DD3F-D3D3-4729-A1EF-34230ADDC12AQ33966207-D5C4EB07-2F89-4263-91AA-26521CDCE183Q34031098-94371592-14A9-46A3-AC56-3871D906395BQ34111171-4416C91C-0743-45FF-B05E-E98D28AFADF5Q34242518-69F1B96C-90D7-4F42-A4F9-9BCDAF5755BDQ34262372-74A10996-5BC3-463B-A166-321BF424AF7BQ34270467-20EF7C1D-B3DF-41A1-894F-DFB40518B9D4Q34335858-C765C01B-0609-4C58-BDFE-63CBA1409E2DQ34508464-A488171E-8702-4CDB-8B43-51132AC859B8Q34522800-676F97FD-D46F-4F7E-A013-6AE641DCEC8DQ35087477-2EE7526C-8BD7-4A58-A914-E1E26B163C1CQ35190051-1306170D-CE6E-4238-BF32-A4B3026ACC96Q35627094-7ED3BCBB-0816-4F7C-B6F0-95BA9455DF43Q35671423-0D44BCDA-8993-4501-8193-FE32A78AD5E5Q35686746-E543CB05-1221-45CF-A476-2ABD10B52D81Q35803734-07C5A8FF-CC28-432F-95EE-4F861658DDE1Q35812842-BF818773-A63A-4239-B5AA-1AFEEF96E31E
P2860
Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Eligibility for recombinant ti ...... oke: a population-based study.
@en
Eligibility for recombinant ti ...... oke: a population-based study.
@nl
type
label
Eligibility for recombinant ti ...... oke: a population-based study.
@en
Eligibility for recombinant ti ...... oke: a population-based study.
@nl
prefLabel
Eligibility for recombinant ti ...... oke: a population-based study.
@en
Eligibility for recombinant ti ...... oke: a population-based study.
@nl
P2093
P1433
P1476
Eligibility for recombinant ti ...... oke: a population-based study.
@en
P2093
Alex Schneider
Arthur Pancioli
Brett Kissela
Charles Moomaw
Daniel Woo
Dawn Kleindorfer
Edward Jauch
James Gebel
Jane Khoury
Jerzy Szaflarski
P356
10.1161/01.STR.0000109767.11426.17
P407
P577
2004-01-22T00:00:00Z